All News
Deucravacitinib, the first oral TYK2 inhibitor, delivers in PsA:
✅ ACR20: 54% vs 34% (placebo)
✅ Skin, joints, fatigue, QoL
📉 Post hoc: less radiographic progression
No new safety signals at W16.
LB0001 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
📊 In POETYK PsA-1, deucravacitinib (TYK2i) significantly improved ACR20 at W16 (54% vs 34% placebo) in bDMARD-naive PsA.
Also improved QoL, skin, and MSK outcomes.
Post hoc: slowed radiographic progression.
Well tolerated & no new safety signals
@RheumNow #EULAR2025 #LB0001
Mrinalini Dey DrMiniDey ( View Tweet)
📱 Axia, a digital therapeutic for #axSpa, led to significant improvements in BASDAI, BASFI & ASQoL in a 12-week RCT.
ASAS20: 51% vs 9%; ASAS40: 23% vs 3%.
Promising app-based intervention comprising individualised exercise, pt education & disease Mx.
@RheumNow #EULAR2025 #LB0002
Mrinalini Dey DrMiniDey ( View Tweet)
from Rituximab to BiTES to CAR T, always looking for deeper B cell depletion
Safety data from CC312 CD19/CD3/CD28, a triple engager in refractory moderate-to-severe SLE
So far so good but how far do we need to go?
#EULAR2025 @RheumNow LB0007
Aurelie Najm AurelieRheumo ( View Tweet)
Older adults with chronic MSK pain report lower physical health—but better mental health—than younger peers.
Fewer missed work days, too.
Is this resilience, adaptation, or shifting expectations with age?
POS0402 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
#EULAR2025 Abstr#LB0001 Phase 3 RCT of Deucravacitinib in psoriatic arthritis met endpoints (ACR20) over PBO at Week 16. Prespecified early radiographic was not significant but post-hoc (without imputed data) showed radiographic inhibition @RheumNow https://t.co/ORUBtUWH31
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2025 @eular_org update
#Recommendations #Rheumatoid #Rx
prof Smolen
subtle diff between former guidelines
MTX+GC
👇
D/C GCs rapidly
👇
If inadequate response
👇
Other csDMARDs are OUT ❎
✅go to bDMARD or tsDMARD*
TsDMARD after safety assessed
@RheumNow RecommendatnII https://t.co/yUrLdk6Eg1
Janet Pope Janetbirdope ( View Tweet)
Presenteeism and absenteeism in RA aren’t just about joints. In this UK study, comorbid anxiety, depression, and OA drove lost productivity.
Treating RA is not enough —holistic management matters.
POS0403 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
🫁 In autoimmune ILD patients from FIBRONEER-ILD (n=325), nerandomilast slowed FVC decline vs placebo and reduced risk of ILD progression events (HR 0.56 for 18 mg BID).
Acceptable safety profile & tolerability.
@RheumNow #EULAR2025 #LB0003 https://t.co/aWsfNOL76n
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2025 Abstr#LB0002 Crossover RCT of use of AXIA - a novel app-based intervention showed improvement in disease activity, functionality & quality of life in pople with Axial #SpA vs usual care. Available in Austria currently - awaiting rollout and in other languages @RheumNow https://t.co/nV4QifyikL
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Self-management of rheum disease is ripe for apps, gamification. How well does it work though?
This app (Axia) in axSpA was basically as good as a biologic.
Maybe you downplay non-pharm management, prob because we don’t do it well. This changes that
#EULAR2025 LB0002 @RheumNow https://t.co/sfhEJFsF89
Links:
David Liew drdavidliew ( View Tweet)
#RA #recommendations #update
Some recommendations were merged
For sure some regions will consider
#Combination #csDMARDs or
Switch to another
👇🤔
#sulfasalazine
#leflunomide
Depends on access, pt preference, disease activity/severity
#EULAR2025 @RheumNow @eular_org https://t.co/QDPcHhvQiV
Janet Pope Janetbirdope ( View Tweet)
🌳#WILLOW: TLR7/8 inhibition with enpatoran led to greater BICLA response, IFN signature reduction & skin improvement (CLASI-50/70) in active SLE vs placebo at 24wks. Most benefit seen in pts with high IFN-GS or GC use. Good tolerability.
@RheumNow #EULAR2025 #LB0004
Mrinalini Dey DrMiniDey ( View Tweet)
Presenting our abstract on remote monitoring in rheumatology at #EULAR2025 @RBNHSFT @UniofReading @HenleyBSchool @RheumNow https://t.co/palWjtX3gM
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Tapering in RA?
In SORAIRO (n=149), pts in remission on ozoralizumab+MTX:
🧪 49% became MTX-free
⏱ 80% spaced OZR to q8w
CDAI ≤10 maintained in >90% if baseline remission + albumin >3.8
LB0006 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
#EULAR2025 Abstr#POS1293 Our cohort study support non-medical switch from Rituximab originator to Biosimilar(RTX-B) or btw RTX-Bs in connective tissue disease. No difference in response/B-cell depletion pre- & post-switch.Only 10% stopped RTX at 5-year.Better than in RA @RheumNow https://t.co/ERPgwQ3gZB
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Leaky pipeline in rheumatology:
In a 23-country survey, women left hospital practice earlier—26% at trainee level vs 7% of men.
Top reasons?
🚫 Unfair promotion
🚫 Poor communication
🚫 No career path
Workplace equity still lags.
POS0407 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
RepurpSS-II RCT (n=46): LEF + HCQ significantly improved systemic disease activity (ESSDAI -4.13) vs PBO in primary #Sjögrens.
⭐️🌱STAR/CRESS response rates also favoured active treatment.
Safe, accessible, affordable option for active disease.
@RheumNow #EULAR2025 #LB0005
Mrinalini Dey DrMiniDey ( View Tweet)
Nerandomilast: the new & improved nintedanib.
Does it work for our rheum pts?
Autoimmune subgroup of FIBRONEER-ILD (NEJM last month)
- mortality benefit vs placebo (this is new)
- well tolerated (minimal increase in diarrhoea vs placebo)
One to watch
#EULAR2025 LB0003 @RheumNow https://t.co/u8fIy7kkKW
Links:
David Liew drdavidliew ( View Tweet)
FIBRONEER-ILD Ph3 PD4B inhibitor Nerandomilast
1100+ pts, 320+ w/ SARD-ILD wk52
FVC relative reduction of decline 9 mg bid 43% 18 mg bid 39% vs. PBO
HR 0.56 time to first acute exacerbation of ILD, hospitalisation for resp cause or death in higher dose group
11% https://t.co/CeXWB2GlOe
Aurelie Najm AurelieRheumo ( View Tweet)
